Compare GIW & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GIW | CBIO |
|---|---|---|
| Founded | 2025 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.4M | 340.4M |
| IPO Year | N/A | N/A |
| Metric | GIW | CBIO |
|---|---|---|
| Price | $9.97 | $19.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 9.1K | ★ 210.4K |
| Earning Date | 01-01-0001 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $355.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $8.72 |
| 52 Week High | $10.01 | $20.58 |
| Indicator | GIW | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 81.34 |
| Support Level | $9.96 | $10.44 |
| Resistance Level | $9.98 | N/A |
| Average True Range (ATR) | 0.01 | 1.46 |
| MACD | -0.00 | 0.92 |
| Stochastic Oscillator | 12.50 | 88.95 |
GigCapital8 Corp is a special purpose acquisition company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.